Preparation and characterization of B-ALL patient samples
Patient . | Sex . | Age, y . | Diagnosis . | Disease status . | % Blasts in the blood . |
---|---|---|---|---|---|
B-ALL Pt #1 | F | 29 | B-ALL | De novo | 75.50 |
B-ALL Pt #2 | M | 45 | CML to Com-B-ALL | Relapse | 35.11 |
B-ALL Pt #3 | F | 72 | B-ALL | De novo | 88.67 |
B-ALL Pt #4 | M | 14 | Pre-B-ALL | De novo | 94.85 |
B-ALL Pt #5 | M | 17 | Pre-B-ALL | De novo | 71.90 |
B-ALL Pt #6 | F | 67 | B-ALL | De novo | 89.83 |
Patient . | Sex . | Age, y . | Diagnosis . | Disease status . | % Blasts in the blood . |
---|---|---|---|---|---|
B-ALL Pt #1 | F | 29 | B-ALL | De novo | 75.50 |
B-ALL Pt #2 | M | 45 | CML to Com-B-ALL | Relapse | 35.11 |
B-ALL Pt #3 | F | 72 | B-ALL | De novo | 88.67 |
B-ALL Pt #4 | M | 14 | Pre-B-ALL | De novo | 94.85 |
B-ALL Pt #5 | M | 17 | Pre-B-ALL | De novo | 71.90 |
B-ALL Pt #6 | F | 67 | B-ALL | De novo | 89.83 |
CML, chronic myelocytic leukemia; Com-B-ALL, common B-cell acute lymphoblastic leukemia; Pre-B-ALL, precursor B cell acute lymphoblastic leukemia.